PEPTIDE YY
Diabetes Mellitus, Type 2
Imperial College Londonprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
50 Active assets in the Diabetes Mellitus, Type 2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Metformin Myopharm Limited | Phase 4 | BBB |
Letrozole ARKAY Therapeutics | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
PEPTIDE YY is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →